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the MPE concept has been widely acknowledged ( 6 -9,15 -42 ) , and has resulted in a number of important insights into the pathogenesis of colorectal cancer, including associations between obesity, physical activity, and aspirin use, and risks of disease occurrence or survival for molecularly defi ned colorectal cancer subgroups ( 12 -14,43 ) .
MPE constitutes a logical strategy for post-genome-wide association study (GWAS) research ( " GWAS-MPE approach " ( 5 )), in which a candidate susceptibility variant may be linked to a specifi c disease subtype ( 44 -46 ) . Interaction analyses between exposures and tumor biomarkers are relatively understudied areas in MPE research, but can demonstrate the capacity of a biomarker to predict response or resistance to lifestyle, dietary, or pharmacological interventions ( 4, 12, 13, 43, 47, 48 ) .
Th rough an appreciation of disease heterogeneity and analyses of molecular alterations that accrue during carcinogenesis, MPE can provide new insights into the mechanisms through which exposures infl uence tumorigenic processes in the colorectum.
THE COLORECTUM AS A RESOURCE FOR MPE RESEARCH
As a result of the widespread application of colonoscopy in symptomatic investigation and screening, the colorectum has become an unparalleled resource for the study of neoplastic initiation and progression. In many other organs, access to premalignant lesions can be diffi cult, especially in the epidemiologic research setting ( 49 ) . Th e colorectum represents an organ in which both cancer tissue and premalignant tissue are readily accessible for molecular analyses, and can provide a model for research on neoplastic evolution in other organs. Th e colorectum is by far the most microorganism-rich organ in the human body, and colonic luminal contents are believed to have an important role in carcinogenesis ( 50, 51 ) . Furthermore, as a contiguous hollow organ, and extension of the external environment, the infl uence of exposure to dietary, microbial, and metabolic constituents of the gut contents can be studied in relation to host factors, including anatomic subsite. Th ese unique features of the colorectum, and of neoplasms arising within it, provide substantial opportunities for research; however, the MPE of colorectal premalignant lesions also poses important challenges.
THE CHALLENGE OF THE UNIQUE TUMOR PRINCIPLE
In the MPE paradigm, genomic and epigenomic variants interact with nongenetic exposures, including dietary, lifestyle, environmental, and hormonal infl uences, to determine disease occurrence and progression diff erently in each patient, through changes in cellular and extracellular interactomes ( 52 ) . As the resulting changes in the tissue microenvironment in one individual will never be exactly the same as those in another, a specifi c disease process in a given individual can be considered unique. Th is concept is embodied in " the unique disease principle " ( 10 ) (or " the unique tumor principle " ( 53, 54 ) ). Th e unique tumor principle gains support from recent genomic and epigenomic projects demonstrating enormous tumor heterogeneity in several cancer types ( 55 -57 ) , from diff erential eff ects of diverse somatic aberrations ( 58, 59 ) , and from the infl uence of host factors on tumor behavior ( 2, 47, 60, 61 ) .
Epidemiology is based on the fundamental premise that we can predict disease occurrence and evolution by inference from other cases of what is nominally the same disease. Th e unique tumor principle therefore poses signifi cant challenges. Nonetheless, the seemingly insurmountable problem of disease heterogeneity can, at least partly, be overcome by molecular tools capable of classifying cases into disease subtypes that share molecular mechanisms and biologic phenotypes ( 62 -72 ) . Th rough molecular classifi cation, we can subtype tumors to predict their evolution and response to interventions with greater accuracy.
MOLECULAR CLASSIFICATION OF COLORECTAL CANCER
Th e commonly used molecular classifi ers in colorectal cancer include mutations in KRAS , BRAF , and PIK3CA ( 73 -79 ) , and global molecular features such as microsatellite instability (MSI) ( 80 -82 ) , the CpG island methylator phenotype (CIMP) ( 15,16, 83 -93 ) , chromosomal instability ( 94 ), and LINE-1 methylation 
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Th e conventional adenoma -carcinoma sequence encompasses three related histological entities, tubular, tubulovillous and villous adenomas, that exhibit multiple molecular pathway variations and account for the majority of colorectal cancers. In this sequence, APC mutation is a common early event ( 1 ); the ensuing disruption of WNT signaling results in a transformed clone of colonocytes that exhibits a dysplastic phenotype and may grow to form a tubular adenoma. In its earliest stage, represented by one or a small number of tubule-shaped crypts, the adenoma is termed an aberrant crypt focus or microadenoma . KRAS mutation is found in up to 50 % of large ( > 1.0 cm) adenomas and is frequently associated with alteration of the polyp architecture from tubular to tubulovillous or villous ( 111 -113 ) .
By defi nition, all adenomas of this conventional sequence show at least low-grade dysplasia -the adenomatous phenotype. Only a small proportion progress to the next level, high-grade dysplasia; this is defi ned by nuclear atypia and architectural disorder of the component glands, leading to cribriform structures. High-grade dysplasia is associated with larger size, villous morphology ( 114 ), TP53 mutation ( 115 ) , and deletion of a region of chromosome 18q ( 115 ) . Chromosomal instability can be demonstrated in late precursor adenomas ( 116 ) and can be morphologically apparent as anaplasia and abnormal mitoses as high-grade dysplasia evolves. Potential causes of chromosomal instability may include level ( 10,95 -97 ) . CIMP status may be divided into CIMP high, CIMP low, and CIMP negative ( 84,98 -103 ) . LINE-1 methylation level can be a continuous classifi er ( 104 -106 ) . Th ese tumor molecular features have been widely investigated in relation to exposures (including diet, smoking, aspirin use, body mass index, physical activity, screening behavior, family history, and heritable genetic variants), immune reaction, colorectal cancer incidence, and outcomes ( 5, 12, 13, 107, 108 ) .
PATHOLOGIC AND MOLECULAR CLASSIFICATION OF COLORECTAL PREMALIGNANT LESIONS
Phenotypic heterogeneity has long been recognized in colorectal premalignant lesions. Historically, we have used lesion size and histopathological classifi cation in an attempt to better predict malignant potential. Well-established pathologic entities include tubular adenoma, tubulovillous adenoma, villous adenoma, hyperplastic polyp, sessile serrated adenoma (SSA) / sessile serrated polyp (SSP), and traditional serrated adenoma (TSA) ( Figure 2 ). In addition, some hamartomatous polyps are considered to be premalignant lesions ( 109 ) . Th e terms SSA and SSP can be used interchangeably, and there is no guideline to enforce one terminology over the other ( 21 ) . In addition to molecular associations of well-established histopathological subtypes, gross morphology of polyps has been associated with tumor molecular features ( 110 ). APC , TP53 , and FBXW7 mutations ( 117 ), AURKA overexpression ( 118, 119 ) , JC virus ( 120, 121 ) , and loss of PIGN , MEX3C , and ZNF516 ( 113 ) .
Th e serrated pathway is an alternative cancer progression sequence that accounts for the development of a minority of colorectal adenocarcinomas ( 21, 122 ) . It comprises a series of polyps that have glands or crypts with a characteristic saw-toothed (serrated) outline, giving the pathway its histological signature and name. Th e serrated lesions commonly have BRAF or KRAS mutation. As a result of BRAF or KRAS mutation, adaptive changes, termed senescence ( 123 ) , occur in the crypt cells that are designed to forestall transformation ( 124 ) . Early lesional crypts containing senescent cells are enlarged to accommodate colonocytes that have normal-appearing nuclei but increased cytoplasmic volume and reduced tendency to slough into the lumen. Th ose abnormal crypts with BRAF mutation commonly show marked serration of the crypts, and the cytoplasm of the cells is fi lled with small mucin vacuoles (microvesicular). Th e KRAS -mutated variant tends to show less prominent serration but marked tuft ing of the surface, and increased numbers of large goblet cells ( 125 ) . Both variants are precursors of hyperplastic polyps that show these respective phenotypes, " microvesicular hyperplastic polyp " and " goblet cell hyperplastic polyp " ( 126 ) . Hyperplastic polyps are small (usually < 5 mm) sessile or fl at polyps. Th ese polyps arise predominantly in the distal colorectum, where they are felt to have limited malignant potential, as refl ected by current surveillance guidelines ( 127 ) . Serrated polyps with disordered growth represent an atypical hyperplastic polyp variant called " SSA / SSP " ( 126 ) . SSAs / SSPs can progress to develop dysplasia ( Figure 2 ), and ultimately evolve into carcinoma ( 21 ) . Th e progression from SSA / SSP to SSA / SSP with dysplasia may be associated with increasing promoter methylation of genes, including MLH1 , CDX2 , and TLR2 ( 128 ) . Th e origins of SSAs / SSPs remain uncertain. It is not currently known whether these polyps develop from a single precursor lesion or arise de novo . In common with microvesicular hyperplastic polyps, SSAs / SSPs are frequently characterized by mutated BRAF . It has therefore been suggested that microvesicular hyperplastic polyps, SSAs / SSPs, and SSAs / SSPs with dysplasia represent parts of a biologic spectrum, and this is supported by an apparent continuum of histological and DNA methylation changes ( 128 -130 ) . Th e endpoint carcinomas of the BRAF -mutated serrated pathway tend to arise in the proximal colon, display CIMP-high, and, as result of epigenetic silencing of MLH1 , also feature genomic hypermutability, manifest as MSI-high ( 131 , 132 ) .
End-point KRAS -mutated serrated pathway carcinomas tend to occur distally, and show mismatch repair profi ciency (or microsatellite stability) and CIMP-low, sometimes in association with MGMT epigenetic inactivation ( 133, 134 ) . Ho wever, it is likely that not all CIMP-low cancers arise through the serrated pathway. One of the precursors of these carcinomas is considered to be TSA, a serrated polyp characterized by exophytic tubulovillous growth and distal location in the colorectum ( 21 ) . KRAS -mutated goblet cell hyperplastic polyp may be a precursor of TSA ( 135 ) . TSA may have heterogeneous pathogenesis; some TSA lesions harbor BRAF mutation or wild-type BRAF and KRAS ( 21 ).
MPE OF COLORECTAL PREMALIGNANT LESIONS
A typical study design for MPE of colorectal premalignant lesions, where an exposure of interest can be examined in relation to molecular subtypes of colorectal neoplasia, is illustrated in Figure 1 . Compared with studies on colorectal cancer ( 4, 5 ) , data on MPE of colorectal premalignant lesions remain relatively sparse ( 30,136 -141 ) .
Th e defi nitive study design for investigating the initiation and progression of colorectal premalignant lesions would be to follow the molecular and biologic evolution of the lesions in vivo , in conjunction with comprehensive data on host exposures. Unfortunately, ethical considerations dictate that this study will never be performed in humans. We therefore require methods that can establish causal relationships between exposures (e.g., dietary, microbiologic, and host genetic factors) and specifi c tumor subtypes, while piecing together the biology of colorectal tumorigenesis from snapshots of the disease at diff erent stages in its natural history. Th e MPE of colorectal premalignant lesions, in synergism with MPE of colorectal cancer, can fulfi ll this role. By way of example, if smoking is shown to be associated with premalignant lesions displaying CIMP-high (or BRAF mutation), it can provide additional evidence for a causal association between smoking and CIMP-high (or MSI-high / BRAF -mutated) colorectal cancer ( 142 -146 ) . An MPE approach can also provide clues to the timing of the carcinogenic eff ect of a given exposure. Considering the above example, if smoking is associated with an increased risk for premalignant lesions with CIMP-high or BRAF mutation, it can provide evidence for an eff ect of smoking on specifi c molecular events at an early phase in carcinogenesis. In contrast, if smoking is asso ciated with CIMP-high or BRAF -mutated colorectal cancer, but not with the risk for premalignant lesions demonstrating these features, it would suggest that smoking facilitates the later progression, rather than initiation, of certain premalignant lesions via specifi c pathways.
Certain caveats are associated with MPE research on colorectal premalignant lesions. One major issue is case ascertainment. Although colorectal cancers may remain asymptomatic over lengthy periods of time, they usually declare themselves eventually -for example, when they bleed, become large enough to obstruct the lumen, or cause systemic symptoms through metastases. Th erefore, in population-based studies, ascertainment of colorectal cancer cases is considered reasonably good; most individuals with colorectal cancer seek medical attention at some point.
In contrast, ascertainment of colorectal premalignant lesions (some of which may never progress to cancer) depends largely on endoscopic screening. In addition to the shift in clinical practice from screening sigmoidoscopy to colonoscopy in the United States, endoscopic and adjunctive screening technologies, as well as the quality of lower endoscopic examinations, have substantially improved over the past decade. Changing endoscopic practice is therefore a potential source of bias and confounding.
Tissue availability represents a further potential source of bias. Th e size and morphology of colorectal premalignant lesions varies enormously. Diminutive lesions may yield only tiny REVIEW Colorectal Neoplasia Molecular Pathological Epidemiology tic criteria for premalignant lesions, especially serrated lesions, have changed considerably over time and may result in interobserver variation among pathologists ( 21, 156 ) . Th us, a cross-comparison of MPE studies on premalignant lesions is challenging. Distinct polyp types likely refl ect diff erent etiologies, and histopathological classifi cation can serve as a surrogate in MPE-type analyses ( 161 ) . Th us, expertise in accurate pathological classifi cation of premalignant lesions is essential to epidemiologic research.
COLORECTAL CONTINUUM
Th e colorectum has traditionally been regarded as a single organ, or as colon and rectum. However, it has long been recognized that clinical and pathological diff erences exist between proximal and distal colon cancers, and a number of infl uential review articles have expounded a dichotomous concept of proximal vs. distal colorectum ( 162 -164 ) . Numerous clinical, pathological, and epidemiologic investigations have adopted this model, and diff erences in key molecular features between proximal and distal colonic tumors have been well described ( 15, 16, 63, 88, 135 ) .
Recently, Yamauchi and colleagues ( 58 ) broke with the prevailing two-colon model and examined molecular features of cancers occurring in nine colorectal subsites. Th is study demonstrated that the frequencies of CIMP-high, MSI-high, and BRAF and PIK3CA mutations in colorectal cancer increase gradually from the rectum to the ascending colon, challenging the notion of an acute transition at the splenic fl exure ( 135 ) . Independent studies have confi rmed similar distributions in molecular features of colorectal cancers ( 34,165 -167 ) . Furthermore, in synchronous colorectal cancers, molecular similarities are proportional to the physical proximity of the two cancers ( 168 ) . A " continuum " hypothesis has therefore been proposed ( 169 ) that embodies the role of luminal contents, microbiota, and host responses in the pathogenesis of colorectal cancer. In support of the continuum model of gut biogeography, the colorectal microbiota and lymphocytic and macrophage infi ltrates appear to transition gradually along colorectal subsites ( 58, 60, 169, 170 ) .
If we continue to use a dichotomous colorectal research model, we will predictably generate data that support the existence of such a model, provided markers of interest vary to some extent along the proximal -distal axis of the colorectum. Investigations on colorectal tumors should attempt to couple molecular classifi ers with detailed subsite location in order to address potential heterogeneity by anatomic location.
IMPLICATIONS IN CANCER PREVENTION
Th e MPE of colorectal premalignant lesions can provide scientifi c evidence for cancer etiologies and can enable us to develop and optimize cancer prevention strategies. First, by providing additional evidence for causality, MPE of colorectal premalignant lesions can help establish colorectal neoplasia risk factors, some of which may be modifi able.
fragments of tissue, or may remain undetected, whereas larger specimens provide abundant material for analysis. Furthermore, the size of a premalignant lesion correlates with its malignant potential, as well as with the feasibility of tumor tissue analyses. With advances in molecular methodologies, smaller quantities of biologic material are required for downstream analyses. Indeed, single-cell whole-genome sequencing is feasible from fresh specimens ( 147 ) . Although fresh tissue yields optimal quality material for molecular analyses, the practicalities of collecting and storing fresh clinical tissue samples oft en prohibit its use on a large scale. Archival formalin-fi xed, paraffi n-embedded (FFPE) tissues, along with their clinical and pathological annotation, represent an immensely valuable resource for MPE research, and most MPE studies to date utilize archival specimens from participants of prospective cohort studies ( 30,136 -141 ) . Although FFPE tissues provide good preservation of microarchitecture for in situ analytic approaches, including immunohistochemical analyses, crosslinking and fragmentation of biomolecules by formalin fi xation aff ects the quality of nucleic acid recovered ( 148 ) . Nonetheless, FFPE tissues have been successfully used for genomic, eigenomic, transcriptomic, and proteomic analyses ( 149 ) . In addition, laser capture microdissection has proved invaluable in addressing tissue and cellular heterogeneity in molecular analyses of FFPE tissues. Laser capture microdissection comes with its own specifi c challenges, including contamination and low tissue quantities ( 150 ) . Th e minimum amount of tissue required for molecular analyses is determined by many factors, including tissue fi xation, storage, age, tissue cellularity, cell ploidy, neoplastic cell abundance, and frequency of the molecular target (e.g., mutation / allele frequency). As little as 10 ng of FFPE-derived DNA may be required for techniques such as comparative genomic hybridization and certain targeted next-generation sequencing approaches ( 151, 152 ) . Furthermore, multiplex transcriptional analyses can be performed in situ , at single cell level ( 153 ) . In contrast to the use of fresh frozen specimens in molecular research, wherein informed consent by the donor is usually the rule, the use of archival FFPE tissues, obtained for diagnostic purposes, raises a variety of bioethical considerations, including consent, sample ownership and custodianship, generation of data on germline genetic variants, and confi dentiality of personally identifi able information ( 154, 155 ) .
Th e anatomic location and morphology of lesions can also infl uence the likelihood of their being detected endoscopically. Th e detection of SSAs, for example, is highly variable among endoscopists ( 156 -158 ) . Th us, serrated neoplastic lesions, particularly those in the proximal colon, may easily be missed at colonoscopy, and it is interesting that molecular markers of the serrated pathway are frequently observed in postcolonoscopy cancers ( 159, 160 ) .
Pathological heterogeneity also poses considerable challenges to the MPE of premalignant lesions. As discussed in the preceding section, colorectal premalignant lesions are inherently hetero genous in terms of biology, morphology, and clinical behavior. In addition, the nomenclature and diagnos- Second, the MPE of colorectal premalignant lesions can provide additional evidence for a mechanistic link between a risk factor and a particular carcinogenic pathway, characterized by a specifi c molecular alteration (such as MSI). Using MSI as an example, if we are ultimately able to identify those individuals with increased susceptibility to the development of cancers demonstrating MSI, we can recommend avoidance of the associated risk factor as a primary preventive measure.
Th ird, in analyses using recurrent premalignant lesions or metachronous cancer as end points, we can assess for interactive eff ects between tumor molecular markers and exposures on the risk of developing subsequent neoplasia. If an interaction can be identifi ed between a tumor molecular feature and an exposure (which may be a modifi able component of diet, lifestyle, or pharmacologic regimen), the molecular feature may serve as a predictive biomarker of response to intervention, warranting further assessment by clinical trials.
CONCLUSIONS
MPE has emerged as an integrative fi eld that addresses molecular heterogeneity of diseases as well as disease distribution and occurrence in large human populations ( 4, 5 ) . Th e MPE of colorectal premalignant lesions can provide unique opportunities for examining the infl uence of an exposure on a specifi c carcinogenic process, and can be synergistic with the MPE of colorectal cancer. Th e recent emergence of the colorectal continuum hypothesis ( 58, 169 ) has added further complexity to the role of gut biogeography in cancer predisposition, and pathological and epidemiologic studies of premalignant lesions must strive to examine detailed colorectal subsites.
Considering future directions in MPE research, the rapidlydeveloping omics disciplines, and other emerging technologies (e.g. interactome, and molecular network mapping), can be applied to tissue repository resources in existing population-based cohort studies, which are unparalleled resources in terms of their large amassed quantities of exposure data. Th is represents a very cost-eff ective approach to advancing integrative MPE science and improving the health of human populations ( 19, 54, 171 ) . Future MPE studies can potentially evolve to embrace advances in in vivo pathology (e.g. endomicroscopy). Ultimately, as molecular patho logical testing becomes routine in clinical practice, molecular classifi cation data should be entered and accumulated within popu lation disease regis tries across the world. Th is will facilitate the adoption of MPE research into standard epidemiologic practice. As epidemiology ultimately attempts to advance our understanding of human disease, epidemiology in this twenty-fi rst century must take into account advances in the molecular biology and pathophysiology of disease processes. One of the most profound challenges in MPE is the paucity of integrative expertise (in molecular patho logy and epidemiology), and future educational reform, involving academic institutions that deliver teaching in medicine and public health, will be required to tackle this problem ( 172 -174 ).
Th ere are caveats associated with the MPE of premalignant lesions, especially with regard to case ascertainment, and we need to be aware of these potential sources of bias. Nonetheless, by careful study design and analyses, MPE can promote unprecedented discoveries that can contribute to better understanding of the development and progression of colorectal neoplasia. Ultimately, MPE of colorectal premalignant lesions can help us achieve our goals of personalized medicine and eff ectively targeted public health interventions, leading to reductions in colorectal cancer incidence and mortality.
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WHAT IS NEW HERE
3 By bridging the gap between normal tissue and malignancy, colorectal premalignant lesions are a unique resource for MPE research.
3 MPE of premalignant lesions can help elucidate the etiologies, mechanisms, and heterogeneity of disease evolution.
3 Opportunities in the study of MPE of premalignant lesions are accompanied by challenges and caveats.
